Event driven focus on CRISPR Therapeutics stock

CRISPR Therapeutics (CRSP) is back on investor radars after recent positive revisions to earnings projections and fresh updates on the commercial rollout of CASGEVY, including reimbursement progress in Germany and ongoing patient initiations.

Despite the recent news flow, CRISPR Therapeutics’ share price is US$48.55 after a 1-day share price return of 2.02%. However, the 30-day share price return is down 15.84%, while the 1-year total shareholder return is up 31.25%, so short-term momentum has cooled compared with the longer-term picture.

If this kind of biotech volatility interests you, it can be useful to see how other healthcare stocks using AI are trading right now with our 30 healthcare AI stocks

With CRISPR Therapeutics’ shares down over the past month but still ahead over the past year, along with optimistic earnings revisions and analyst targets well above the current US$48.55 price, is there still a buying opportunity here, or is the market already pricing in future growth?

Price to book of 2.6x: Is it justified?

On Simply Wall St's numbers, CRISPR Therapeutics trades on a P/B of 2.6x, which screens as good value against selected peers, even though the stock is unprofitable and small in revenue terms.

P/B compares the company’s market value to its net assets on the balance sheet and is often used when earnings are negative or volatile, as is common in early stage biotech. For CRISPR Therapeutics, the current 2.6x P/B suggests investors are paying a little over two and a half times the company’s book value for exposure to its gene editing platform and pipeline.

Against a peer set where the average P/B is 7x, CRISPR Therapeutics looks cheaper on this metric. However, within the broader US biotech industry the stock is described as slightly expensive relative to the 2.4x sector average. That split highlights how sentiment can differ between narrower peer groups and the wider industry, and it also points to a level the market could potentially move toward if expectations change.

Result: Price to book of 2.6x (UNDERVALUED).

However, investors still face key risks, including CRISPR Therapeutics’ US$568.534 million net loss and the possibility that early stage programs do not progress as hoped.

Another view: our DCF model

While the 2.6x P/B ratio indicates value compared with peers, our DCF model suggests a significantly higher value, with CRISPR Therapeutics trading at US$48.55 versus an estimated future cash flow value of US$179.29. That gap raises a clear question: is the market being too cautious about long-term cash generation?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals or early opportunity: either way it makes sense to review the numbers yourself, compare the upside and the risks, and then weigh the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If CRISPR Therapeutics has your attention, do not stop here. The market is full of other potential opportunities that could suit your goals just as well.

• Scan for quality at a discount by reviewing companies highlighted in our 51 high quality undervalued stocks and see which stocks currently stand out on fundamentals.
• Strengthen your income stream by checking out higher yielding opportunities in the 10 dividend fortresses that still focus on resilience.
• Prioritize resilience and peace of mind by focusing on the 67 resilient stocks with low risk scores, where stocks are filtered for lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.